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Alzheimer’s disease (AD) and vascular dementia (VaD) are the most common cause of
dementia. Cerebral ischemia is a major risk factor for development of dementia. 123I-FP-
CIT SPECT (DaTScan) is a complementary tool in the differential diagnoses of patients
with incomplete or uncertain Parkinsonism. Additional application of DaTScan enables
the categorization of Parkinsonian disease with dementia (PDD), and its differentiation
from pure AD, and may further contribute to change the therapeutic decision. The
aim of this study was to analyze the vascular contribution towards dementia and mild
cognitive impairment (MCI). We evaluated the utility of DaTScan for the early diagnosis of
dementia in patients with and without a clinical vascular component, and the association
between neuropsychological function, vascular component and dopaminergic function
on DaTScan. One-hundred and five patients with MCI or the initial phases of dementia
were studied prospectively. We developed an initial assessment using neurologic
examination, blood tests, cognitive function tests, structural neuroimaging and DaTScan.
The vascular component was later quantified in two ways: clinically, according to the
Framingham Risk Score (FRS) and by structural neuroimaging using Wahlund Scale Total
Score (WSTS). Early diagnosis of dementia was associated with an abnormal DaTScan.
A significant association was found between a high WSTS and an abnormal DaTScan
(p < 0.01). Mixed AD was the group with the highest vascular component, followed by
the VaD group, while MCI and pure AD showed similar WSTS. No significant associations
were found between neuropsychological impairment and DaTScan independently of
associated vascular component. DaTScan seems to be a good tool to discriminate,
in a first clinical assessment, patients with MCI from those with established dementia.
There was bigger general vascular affectation observable in MRI or CT in patients with
abnormal dopaminergic uptake seen on DaTScan.
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Introduction
Dementia is a chronic brain syndrome which affects 35.6 million
people worldwide and this number is expected to triple by 2050
(115.4 million). Thus, it has an enormous impact on health care
provision currently costing the world more than US$ 604 billion
per year (Wimo et al., 2013).
The most frequent cause of dementia in the elderly is
Alzheimer’s disease (AD), followed by vascular dementia (VaD),
Parkinson disease with dementia (PDD) and Lewy Body
dementia (LBD). Together these account for over 90% of cases
of dementia in the elderly (Albanese et al., 2007).
Although they have distinct features, the different types of
dementia overlap clinically and pathologically, especially in the
early stages and particularly in regards to the contribution
of brain ischemia (Iadecola and Gorelick, 2003). Increasing
evidence demonstrates that ischemia is not only an additive cause
of brain damage in all types of dementia but also contributes
specifically to the underlying disease processes (Niwa et al.,
2002; Iadecola and Gorelick, 2003) Many cardiovascular risk
factors (CVRF), such as hypertension, diabetes, dyslipidemia,
and smoking increase the risk of AD, suggesting a vascular
contribution to the etiology of AD. Ischemia upregulates
and deregulates the entire amyloidogenic cascade. Within the
framework of the neurovascular unit, vascular dysfunction may
reduce the clearance of β-amyloid (Aβ) via the blood brain
barrier or indirectly increase Aβ deposition. Amyloid deposition
is considered the pivotal event in the AD pathological cascade,
but whether the accumulation is accelerated by CVRF remains
unclear (Breteler, 2000; Purnell et al., 2009; Figure 1). The
evidence is stronger for VaD and AD, but there is a lack of
research into the potential contribution of ischemia to LBD
or PDD.
Other studies showed that most CVRF also increase the risk
for AD (Tatemichi et al., 1994; Tanimukai et al., 1998; Kalaria,
2012). In large epidemiological studies, the prevalence of AD
is reported to increase with the severity of atherosclerosis, the
presence of atrial fibrillation, hypertension, diabetes mellitus,
hyperinsulinemia and insulin resistance, and a previous stroke
(Skoog et al., 1996; Leibson et al., 1997; Ott et al., 1997).
Antihypertensive treatments can prevent stroke and also the risk
of dementia (Sörös et al., 2013). Further, abnormalities in the
cerebral white matter thought to be ischemic in nature are more
common in AD than controls, and its severity correlates with
mild cognitive impairment (MCI) progression to AD (Scheltens
et al., 1992; Eckerström et al., 2011).
The occurrence of both AD pathology and vascular brain
injury is very common, especially amongst the oldest of old
and can be classified as mixed AD. Although epidemiologic
studies report that vascular risk factors for arteriosclerosis
increase the risk of incident AD, both autopsy, MRI and amyloid
positron emission tomography (PET) studies indicate that AD
and vascular lesions contribute additively, but independently,
to the risk of dementia. The literature confirms the malignancy
of AD and highlights the adverse effects of microinfarcts on
cognitive function. For the clinical diagnosis of mixed AD,
the presence of AD can be recognized by neuropsychological
profile, structural imaging, cerebrospinal fluid biomarkers,
and glucose PET and amyloid PET imaging. The diagnosis
of mixed AD, however, still hinges predominantly on the
structural MRI findings (Chui and Ramirez-Gomez, 2015).
Studies on neuroimaging have reported that over 70% of
patients consulting for neurodegenerative disease have abnormal
MRI findings suggestive of a vascular component (Mills et al.,
2007). White matter hyperintensities (WMHs) on brain MRI
reflect cardiovascular risk profiles, and greater WMH volume is
associated with cerebral hypometabolism and cognitive decline,
particularly in tests of executive function (DeCarli et al.,
1995; Jeerakathil et al., 2004; Carmichael et al., 2010). These
structural and cognitive changes were associated with CVRF.
The Framingham Stroke Risk Profile score, a composite risk
score of CVRF that measures 10-year probability of stroke,
was negatively associated with total cerebral brain volume and
positively related to prevalent WMHs. The association between
multiple CVRF was examined by a number of studies using
the Framingham Stroke Risk Profile. High Framingham scores
correlate with poor cognitive performance (Wolf et al., 1991;
Elias et al., 2004; Jeerakathil et al., 2004). These results confirm
that ischemia is a major risk factor for dementia. In fact,
10% of stroke patients develop dementia shortly after their
first stroke and more than a third develop dementia after
recurrent strokes. Subjects not developing dementia as a direct
consequence of a stroke have a 10-fold increase in the risk
of dementia over the next 5 years (Pendlebury and Rothwell,
2009).
Neuroimaging techniques play a major role as diagnostic
instruments (Visser et al., 2012). In particular, emission
tomography (single photon emission computed tomography,
SPECT and PET) provides a unique tool to investigate functional
and neurochemical changes, both in those with established
dementia and at risk of subsequent cognitive decline (de Souza
et al., 2012; Herholz, 2012).
AD is characterized by bilateral temporoparietal
hypoperfusion on SPECT and hypometabolism on PET,
which may precede the onset of clinical dementia. Similar
changes can be demonstrated in those with MCI and in those
genetically at risk of developing AD (Brun and Englund, 1986;
Vanitallie, 2013). In turn, VaD is related to multiple, asymmetric,
perfusion deficits secondary to brain multi infarction (Chen
et al., 2013).
In contrast, in LBD medial parietal and occipital perfusion
deficits are seen together with mainly pre-synaptic dopaminergic
changes, most commonly a reduction in the striatal pre-
synaptic dopamine transporter (DAT) which can be visualized
using appropriate tracers [e.g., 123I-N-3-fluoropropyl-2beta-
carbomethoxy-3beta-4-iodophenyl tropane (123I-FP-CIT
SPECT); McKeith et al., 2005; Cummings et al., 2011].
Thus, advanced functional imaging has a promising potential
in supporting dementia diagnosis. Indeed, imaging of the DAT
defines integrity of the dopaminergic system, and hence its
degeneration in vivo (Varrone and Halldin, 2010). Its main
clinical application is in patients with mild, incomplete, or
uncertain Parkinsonism (Weng et al., 2004; Tolosa et al., 2007;
Eshuis et al., 2006). That is, striatal uptake correlating with
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FIGURE 1 | In VaD, cerebrovascular risk factors induce neurovascular
dysfunction leading to brain dysfunction and damage. In Alzheimer’s
disease (AD), cleavage of amyloid precursor protein by by β- and γ-secretases
leads to Aβ accumulation, which also causes brain dysfunction and damage.
Although individually these pathways are capable of inducing cognitive
impairment, their interaction enhances their pathogenic effects. Thus, Aβ
induces vascular dysregulation and aggravates vascular insufficiency, thereby
enhancing the brain dysfunction and damage associated with vascular risk
factors. In addition, the hypoxia-ischemia resulting from the vascular
insufficiency increases Aβ cleavage from APP and reduces Aβ clearance
through the cerebral vasculature, promoting Aβ accumulation and the attendant
deleterious effects on the brain (Iadecola, 2010).
disease severity, in particular bradykinesia and rigidity. Also, it is
a useful tool in the monitoring of progression in clinical trials of
potential neuroprotective drugs and in differentiating juvenile-
onset Parkinson’s disease (abnormal 123I-FP-CIT SPECT) from
dopa-responsive dystonia (normal 123I-FP-CIT SPECT; Marshall
and Grosset, 2003).
Dopamine loss is seen even in the earliest clinical
presentations of true Parkinsonism; a normal scan suggests
an alternative diagnosis such as essential tremor, drug-induced
Parkinsonism, or psychogenic Parkinsonism (Cummings et al.,
2011). Congruence between working clinical diagnosis and DAT
imaging increases over time in favor of baseline 123I-FP-CIT
SPECT imaging results. Additional applications, especially
accurate when combining with other neuroimaging tools such
as FDG-PET, characterize dementia with Parkinsonian features
(Cummings et al., 2011; Garibotto et al., 2013). Furthermore, it
is possible to differentiate AD from LBD [normal tracer uptake
in AD and abnormal in dementia with Lewy bodies (DLB) with
sensitivity and specificity of 78−88% and 94−100%, respectively;
McKeith et al., 2005].
Regarding the vascular component involved in dementia, the
role of nuclear medicine imaging in the diagnosis of vascular
Parkinsonism (VP) or VaD has been addressed by only a few
studies up to now and with non-definitive results. Some of these
suggest normal 123I-FP-CIT SPECT (Gerschlager et al., 2002;
Lorberboym et al., 2004; García Vicente et al., 2005) in VP while
others suggest reduced 123I-FP-CIT binding as well as a lower
mean asymmetry index than Parkinson’s disease (Zijlmans et al.,
2007). In general more studies reported higher percentage of
normal FP-CIT SPECT in VP patients (Bouwmans et al., 2013).
The aim of this study was to analyze the vascular contribution
towards dementia and MCI. We evaluated the utility of FP-
CIT SPECT for the early diagnosis of dementia in patients with
and without a clinical vascular component, and the association
between neuropsychological function, vascular component and
dopaminergic function on FP-CIT SPECT.
Materials and Methods
Subjects
The study population included 105 patients. They were recruited
prospectively from the outpatient Dementia and Stroke Unit.
We included patients with clinical diagnosis of MCI (n = 50),
probable dementia (AD and VaD, n = 37), and Parkinson disease
with dementia (PDD and DLB, n = 18; Table 1).
TABLE 1 | Distribution of different diagnoses in our study group.
N Age Sex M:F
Mild cognitive impairment (MCI) 50 72 ± 8 26:24
Alzheimer’s disease (AD) 31 76 ± 7 12:19
Parkinson disease with dementia (PDD) 12 77 ± 6 10:2
Vascular dementia (VaD) 6 73 ± 9 3:3
Lewy body dementia (LBD) 6 73 ± 11 3:3
Data are presented as mean (±SD) or number.
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Dementia was diagnosed according to the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition (DSM-
IV), and AD based on the criteria of the National Institute
of Neurological and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association for
definite, probable, or possible. Independently, two trained
neurologists made the diagnosis and the final diagnosis was
established by consensus. Patients with hemispheric vascular
accident or severe isolated aphasia were not included. Also,
patients with prior cranial trauma, severe heart, kidney or
liver disease, cancer or infection signs were excluded from our
study.
Baseline Assessment
Demographic and Clinical Variables and
Cardiovascular Risk Profile
Demographic data included age and gender. We also
recorded medical history including data such as CVRF and
psychiatric disorders. CVRF were extracted from the medical
history: hypertension, dyslipidemia, Diabetes Mellitus, smoke
habit, family history of dementia or cardiovascular disease,
presence of peripheral vascular disease (PVD), coronary artery
disease (CAD) or prior stroke. Cardiovascular risk score was
calculated using the recently developed Framingham General
Cardiovascular Disease Risk from the Framingham Heart
Study (Wolf et al., 1991; D’Agostino et al., 2008). Framingham
Risk Score (FRS) was estimated in all patients according to
age, gender, total cholesterol levels, HDL levels, systolic blood
pressure, hypertension treatment, smoking habit, diabetic
status, and vascular disease (CAD, PVD, stroke). Those patients
presenting moderate or high FRS were categorized as having a
clinical vascular component, while all the rest were considered as
not having it.
Data were provided by the patient and/or caregiver or
extracted from medical reports if available.
Physical Examination
Neurological clinical examination was performed. Assessments
were undertaken according to the local practice. The Mini-
Mental State Examination (MMSE) was administered as a
cognitive screening test. The effect of cognitive impairment on
global functioning was measured with the Clinical Dementia
Rating Scale (CDR) and the Global Deterioration Scale
(GDS). Instrumental activities of daily living (IADL) and
ADL functions were measured with the Blessed Dementia
Rating Scale (BDRS), the Bayer ADL or self-rating Bayer ADL
scale.
Motor sub-scale of the Unified Parkinson’s Disease Rating
(UPDRS- III) was used as a measure to help in the description
of the extrapyramidal symptoms (EPS). Neuropsychiatric
symptoms were measured with the Neuropsychiatric Inventory
(NPI) and depression rates on the elderly were measured with
the Yesavage scale.
Neuropsychological Battery
A standardized protocol was administered by a trained
neuropsychologist. We selected a short version of the Barcelona
test. The domains tested were orientation, attention, immediate
and differed memory, language, praxis, gnosis, executive
functions and working memory. Neuropsychologists were
also asked to give a GDS of the cognitive impairment
evaluated.
Complementary Physical Examinations
General blood tests were realized including lipid profile.
According to our laboratory criteria, lipid abnormal profile was
defined as cholesterol levels higher than 200 mg/dl, high density
lipoprotein cholesterol (HDL) lower than 56 mg/dL if men and
lower than 65 mg/dL if women, low density lipoprotein (LDL)
cholesterol higher than 100 mg/dl and triglycerides higher than
190 mg/dL.
Neuroimaging Study
In addition to the clinical vascular component defined
using FRS, the vascular contribution in each group of
patients was also quantified from WMHs on anatomic
neuroimaging.
MRI and CT imaging
MRI was used preferentially, if not available CT was used.
MRI was performed on a Symphony MR A-35 1.5 T scanner
and processed using MR 2004 A Syngo software. CT imaging
was performed on Siemens Sensation Somaton E scanner and
processed using the software CT 2007 –S 16 C. Axial CT
or T2 weighted MRI images were used for the quantification
of the vascular component using a validated score according
to Wahlund scale (from 0 to 3; Wahlund et al., 2001). The
Wahlund scale was used in the analyses of WMHs in five
cerebral areas in both hemispheres: frontal, parieto-occipital,
temporal lobes, infratentorial area and basal ganglia. WMHs
on MRI were defined as ill-defined hyperintensities >5 mm
on T2 images, and on CT as ill-defined and moderately
hypodense areas of >5 mm. Lacunes were described as well-
defined areas of >2 mm with attenuation (on CT) or signal
characteristics (on MRI) the same as cerebrospinal fluid. If
lesions with these characteristics were <2 mm, they were
considered perivascular spaces. Changes in the basal ganglia were
rated in the same way and considered WMHs even if located
in the gray matter nuclei, which contains a small amount of
white matter. The Total Score of the Wahlund Scale (WSTS) was
finally quantified as the mean value of the five cerebral areas
analyzed.
Molecular imaging of dopaminergic activity by 123I-FP-
CIT SPECT
SPECT images were acquired on a 2 headed gamma camera
hybrid SPECT-TC Infinia HW4 General Electronic with a high
resolution collimator. Images were acquired 3 h after a single
intravenous injection of 5 mCi (111–185 MBq) of the radiotracer
123I Ioflupane. Subjects underwent standard thyroid blocking
with potassium iodide oral administration (120 mg) 1–4 h
before and 12–24 h after the radiotracer injection. Images were
assessed using a dichotomous division of normal (0) vs. lower
uptake (1).
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Statistical Analyses
Demographic parameters were expressed as absolute values
and percentages for the qualitative variables and by mean and
standard deviation for the quantitative variables.
In bivariate analysis, qualitative variables were compared
using the χ2 test or Fisher exact probability Test, when
appropriated. To complete the comparison between qualitative
and quantitative variables Student’s t-test was carried out.
For the mean comparisons ANOVA test was used. Finally,
Pearson correlation coefficients were used to examine the
relationship between quantitative variables. A two-sided P
value of <0.05 was used to assess statistical significance.
For significant variables, 95% confidence intervals (CI) were
established.
Statistical analyses were performed using the Statistical
Package for the Social Sciences SPSS 17.0 (SPSS Inc., Chicago,
IL, USA).
Ethical Considerations
This study was done in accordance with the Review Board and
Ethics Committee of our center. Written informed consent was
always obtained from patients.
Results
Subject Demographics
Subject’s demographic characteristics, CVRF, results
of neurological, neuropsychological and neuroimaging
examination frequencies of MCI group compared to the
dementia group are shown in Table 2. In Table 3 the same
features are described as N(%) for each dementia type and
also MCI.
Vascular History and Risk Factors
Within clinically diagnosed AD, 7 out of 31 patients had vascular
lesions on imaging and were classified as mixed AD. However,
none of the CVRF studied was associated with dementia. Similar
frequencies of hypertension were seen in MCI and dementia
(62 vs. 66%, respectively). The same smoking habit frequency
was found in MCI compared to dementia (21%). Zero percent
smokers were found in the VaD group and the highest frequency
existed in DLB (40% smokers).
HDL levels were normal for all the different subtypes of
dementia except DLB and PDD, which presented with lower
levels (36 ± 22 mg/dL and 47 ± 13 mg/dL, respectively).
Elevated LDL levels were found in AD (136± 48 mg/dL). Overall
dementia presented with general abnormal triglycerides levels
(171± 59 mg/dL).
Regarding the clinical component according to FRS, no
significant association was found with dementia compared to
MCI (frequencies of 64% and 63%, respectively). When studying
the different types of cognitive impairment separately, PDD
showed the highest frequency (92%) followed by VaD (67%),
MCI (63%), DLB (60%) and AD (53.6%).
Related to the presence of PVD this showed the highest
frequency within the VaD group (20%) and no significant
differences were observed between MCI (5%) and overall
TABLE 2 | Subject’s demographic characteristics, distributions of CVRF,
results of neurological, neuropsychological and neuroimaging
examination in MCI group compared to the dementia group.
N (%) MCI Dementia
Sex M:F 26 (52):24 (48) 29 (53):26 (47)
Age 72 ± 8 75 ± 8
Vascular component 14 (29) 14 (26)
EPS 0 (0) 17 (31)
Hypertension 29 (62) 31 (66)
Dyslipidemia 16 (34) 17 (36)
Diabetes mellitus 12 (26) 15 (32)
Smoking or ex-smoking 10 (21) 10 (21)
PVD 2 (5) 3 (7)
CAD 4 (10) 6 (14)
Prior stroke 15 (37) 11 (26)
Total cholesterol 194 ± 40 190 ± 47
HDL cholesterol 50 ± 18 51 ± 21
LDL cholesterol 108 ± 63 103 ± 55
Triglycerides] 137 ± 100 171 ± 59
HACHINSKI 4 ± 3 4 ± 3
GDS fast 3 ± 1 4 ± 1
MMSE] 25 ± 4 21 ± 5
UPDRS-III motorsub-scale] 9 ± 9 37 ± 15*
WSTS] 0.5 ± 0.4 0.7 ± 0.6
123 I-FP-CIT SPECT decrease uptake] 7 (21) 14 (45)
Numbers and % are presented for each group. ]p < 0.05; ∗This refers only to PDD
group.
dementia (7%). The dementia group presented with higher
frequency (14 vs. 10% in MCI) of CAD, and similar frequencies
were seen in AD, VaD, PDD (13, 20 and 22% respectively).
MCI patients had more prior strokes than dementia patients (37
vs. 26%). When ischemic lesions were examined according to
Hachinski ischemic scale, VaD had the highest score (6± 5 total
score).
Parkinsonism Features
The presence of extrapyramidal signs (EPS) was measured with
UPDRS III (motor subscale) test. In our sample, 17 patients
presented with EPS, corresponding to all patients with PDD and
DLB. UPDRS III scores were higher in PDD than in MCI (mean
values of 37 vs. 9 in a 0–108 scale).
Cognitive Test Function and Neuropsychological
Battery
Our population of probable dementia patients did not show
significant differences regarding MMSE scores among dementia
subtypes (mean MMSE score for probable dementia and MCI
was 21 and 25, respectively).
A significant association was found between dementia and the
global neuropsychological function, measured as a summary of
the different affected areas (p = 0.025).
When we analyzed each neuropsychological area separately,
patients with overall dementia (regardless of dementia subtype)
had a higher frequency of affectation of the orientation domain
compared to those with MCI (35% in MCI and 58% in dementia,
Frontiers in Systems Neuroscience | www.frontiersin.org 5 July 2015 | Volume 9 | Article 99
Garriga et al. 123 I-FP-CIT SPECT in dementia
TABLE 3 | Subject’s demographic characteristics, CVRF, results of neurological, neuropsychological and neuroimaging examination in different dementia
subtypes and in MCI patients.
N (%) AD VaD PDD LBD MCI
Vascular component 7 (23) 5 (83) 2 (17) 0 14 (28)
EPS 0 0 12 (100) 6 (100) 0 (0)
Hypertension 18 (67) 4 (80) 8 (80) 1 (17) 29 (62)
Dyslipidaemia 9 (33) 2 (40) 4 (40) 2 (33) 16 (34)
Diabetes mellitus 6 (22) 2 (40) 4 (40) 3 (50) 12 (26)
Smoking or ex-smoker 6 (22) 0 2 (20) 2 (33) 10 (21)
PVD 1 (4) 1 (20) 1 (11) 0 2 (5)
CAD 3 (13) 1 (20) 2 (22) 0 4 (10)
Prior stroke 5 (21) 3 (60) 2 (22) 1 (17) 15 (37)
Total cholesterol 205 ± 49 165 ± 39 172 ± 34 186 ± 62 194 ± 4
HDL cholesterol 56 ± 17 66 ± 30 36 ± 22 47 ± 14 50 ± 18
LDL cholesterol 136 ± 48 83 ± 22 82 ± 56 74 108 ± 63
Triglycerides 144 ± 65 84 ± 31 97 ± 46 117 ± 68 137 ± 100
HACHINSKI 4 ± 3 6 ± 5 5 ± 3 2 ± 2 4 ± 4
GDS fast 4 ± 1 NA 4 ± 1 NA 3 ± 1
MMSE 22 ± 5 22 ± 6 19 ± 3 19 ± 6 25 ± 4
UPDRS-III motor sub-scale NA NA 38 ± 17 33 ± 4 9 ± 9
WSTS 0.6 ± 0.5 0.7 ± 0.6 0.8 ± 0.5 0.3 ± 0.4 0.5 ± 0.4
123 I-FP-CIT SPECT lower uptake 3 (23) 0 (0) 7 (78) 4 (80) 7 (21)
Numbers and percentage are presented.
p < 0.05). Speech was also more affected in dementia (16% in
MCI and 39% in dementia, p < 0.05) and gnosis alterations was
not found in MCI (0%) while 13% of patients with dementia
presented with gnosis alterations (p < 0.05). No significant
differences were found in relation to the other tested functions
(memory, working memory, attention, praxis).
Association Between Vascular Component and
WSTS
We used the WSTS to quantify the vascular lesions observed
either in MRI or CT and then studied their association with the
qualitatively established clinical vascular component.
An association was found between the presenting clinical
vascular component according to FRS and WSTS calculated
using MRI and CT images. Patients presenting with a clinical
vascular component showed a higher mean WSTS (mean WSTS
0.7 vs. 0.4, p< 0.05 respectively).
We also found significant association regarding frontal,
basal ganglia, infratentorial and Wahlund Scores with vascular
component according to FRS (p< 0.05).
Association Between WSTS and Clinical Diagnoses:
Mixed AD has Higher WSTS than Other Dementia
Types or MCI
One of our aims was to study the contribution of the clinical
vascular component towards brain damage and dementia.
Hence, after seeing association between clinical vascular
component according to FRS and WSTS, we wanted to look
at the association between having a high WSTS and the
clinical diagnoses of either dementia or MCI. Although not
being statistically significant, the highest mean WSTS was
found in the PDD group of patients. Moreover, when AD
patients with clinical vascular component (mixed AD, 7/31
patients) were separated from the pure AD they appeared
to have the highest WSTS. In contrary, pure AD showed
a lower WSTS, even lower than that observed in MCI
(Figure 2).
Association between area-specific WSTS and clinical
diagnosis was only found in infratentorial WSTS, which is linked
to PDD (p< 0.05).
FIGURE 2 | Mean values of wahlund scale total score (WSTS)
measured on MRI/CT for each patient group. AD patients with clinical
vascular component (mixed AD) have the highest score, followed by VaD and
PDD. DLB showed the lowest score, while mild cognitive impairment (MCI)
and pure AD presented with comparable values.
Frontiers in Systems Neuroscience | www.frontiersin.org 6 July 2015 | Volume 9 | Article 99
Garriga et al. 123 I-FP-CIT SPECT in dementia
FIGURE 3 | Dopaminergic uptake distribution observed on 123I-FP-CIT
SPECT for MCI and dementia group.
Association Between Clinical Diagnoses and Uptake
in 123I-FP-CIT SPECT
123I-FP-CIT SPECT was available in 33 MCI and 31 dementia
patients (13/31 AD, 4/6 VaD, 9/12 PDD, 5/6 LBD, respectively),
a total of 61% of studied population. A significantly higher
frequency of decreased uptake in 123I-FP-CIT SPECT was found
in patients with dementia compared to MCI (21% patients
with decreased uptake in MCI vs. 45% patients in dementia
group, p < 0.05; Figure 3; Table 2). As expected, patients with
Parkinsonism (DLB and PDD) showed the highest frequency of
decreased dopaminergic uptake (80% in DLB and 78% in PDD;
Table 3).
Association Between WSTS and Dopaminergic
Uptake in 123I-FP-CIT SPECT
A significant association was found between dopaminergic
uptake seen on 123I-FP-CIT SPECT and the vascular component
quantified using WSTS (p < 0.01; Figure 4). Thus, patients
presenting higher WSTS more frequently showed an abnormal
123I-FP-CIT SPECT image (p< 0.01; Figure 5).
Nevertheless, no significant association was found between an
abnormal 123I-FP CIT SPECT image and the vascular component
according to FRS.
No Association Between Dopaminergic Uptake
123I-FP-CIT SPECT nor WSTS and
Neuropsychological Function
In relation to the association between dopaminergic uptake
observed in 123I-FP-CIT SPECT and the neuropsychological
function examined by an ordinary test battery. No
significant results have been obtained when studying each
neusopsychological function separately, and neither with the
overall performance on neuropsycological tests. No relationship
was found between neuropsychological function and the clinical
vascular component measured using WSTS.
Discussion
In this study we aimed to analyze the contribution of vascular
component (assessed clinically and on neuroimaging) to clinical
diagnoses of the common types of dementia and MCI. We
tested the potential application of 123I-CIT-SPECT imaging
FIGURE 4 | Association between WSTS and abnormal dopaminergic
uptake in 123I-FP-CIT SPECT (p < 0.01).
FIGURE 5 | MRI and 123I-FP-CIT SPECT Images from a representative
patient to show relation existing between abnormal MRI and uptake
on 123I-FP-CIT SPECT. (A) MRI T2-potentiated showing diffuse cerebral
atrophy with increased size and depth of cerebral grooves and ventricular
supratentorial enlargement. Multiple lacunar chronic infarctions, some of those
were hemeorrhagic in the lenticular and head of caudate nuclei. Chronic
periventricular ischemia leucoencephalopaty and focal hyperintensities in
parietal frontal and temporal bilateral white matter WSTS = 1.6.
(B) 123 I-FP-CIT SPECT from the same subject showing detectable decreased
uptake in right putamen.
in dementia, particularly when the vascular component is
present. We looked at the association between having vascular
component and presenting an abnormal 123I-CIT-SPECT.
Finally, we studied the association between neuropsychological
function and vascular component or abnormal 123I-CIT-SPECT.
A better understanding of the association between these variables
could help providing new tools for a more accurate and early
diagnoses of common types of dementia.
Our results showed an association between clinical vascular
component according to FRS and quantification of the vascular
component using WSTS on MRI and CT images. These results
are in line with what would be expected and confirm the
reliability of the quantification of WMHs lesions using Wahlund
scale in our population (Wahlund et al., 2001). Further, it
confirms that it was a well selected population. The association
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between WMHs for each brain area separately was significantly
different in frontal, basal ganglia and infratentorial areas.
However, no association was found within the temporal area,
which actually would be the most likely, considering that
most frequent types of AD-like dementia are characterized by
temporo-parietal alterations (Fischer et al., 1990; Jabłon´ski et al.,
2011; Marchesi, 2011).
It was observed in previous studies that vascular lesions
contribute to cognitive decline. It was suggested that
cerebrovascular lesions induce amyloid deposition perhaps
accelerating the process of dementia (Garcia-Alloza et al., 2011;
Pluta et al., 2013). Although, we did not find a significant
association between the different clinical diagnoses of cognitive
impairment and WSTS, we have observed a notable frequency
of the vascular component on neuroimaging within the AD
group. The later group probably was formed by mixed AD
population. These findings confirmed the fact that vascular
accident history contributes to the etiology and/or progression
of dementia. Patients with mixed AD and PDD had a high
WSTS, even higher than in patients with VaD. Although
not being statistically significant, these results are in line
with the association between AD or PDD and WMHs. No
conclusions can be drawn related to overall dementia and MCI
WSTS.
In relation to the particular areas affected by ischemic lesions
and each diagnoses, we only found a significant association
relating to the infratentorial region in PDD. This could be
explained by the fact that in our PDD group there was a high
frequency of VP, as this group presented with a high mean
of WSTS (0.8 ± 0.5) with 92% frequency of clinical vascular
component according to FRS. Further, the non-association
of VaD and any specific brain region could be due to a
diffuse pattern of this type of dementia, unusual low FRS
of this group and/or the few number of patients in this
group.
Furthermore, we evaluated the potential utility of 123I-FP-CIT
SPECT as a diagnostic tool to discriminate dementia from MCI,
and differentiate among different dementia types, emphasizing
on dementia with a vascular component. Our study showed
that 123I-FP-CIT SPECT is a useful tool to discriminate MCI
from overall dementia subtypes. This is a promising observation,
since it is a major clinical priority to be able to more accurately
confirm dementia diagnoses and predict MCI progression.
However, in our study we could not demonstrate the utility of
123I-FP-CIT SPECT to discriminate among different dementia
types.
As expected, most of patients with PDD and all but
one of those with LBD showed an abnormal 123I-FP-CIT
SPECT. Nevertheless, three patients with PD did not show an
abnormal 123I-FP-CIT SPECT, suggestive of possible iatrogenic
Parkinsonism. We hypothesized that patients with VaD could
show an abnormal 123I-FP-CIT SPECT if ischemic lesions
affected directly or indirectly the dopaminergic control of
cortical-striatal circuits. This was not seen in our study
probably because of the small number of patients with
VaD (n = 6), none of which showed abnormal 123I-FP-CIT
SPECT.
Once we had demonstrated the utility of 123I-FP-CIT
SPECT to differentiate dementia vs. MCI, we then studied the
association between abnormal 123I-FP-CIT SPECT and presence
of the vascular component clinically assessed with the FRS
and quantified on neuroimaging using WSTS. An association
between the vascular component according to FRS and abnormal
123I-FP-CIT SPECT was not found, but the association between
dopaminergic function and WSTS was statistically significant.
Thus, our results showed that 123I-FP-CIT SPECT discriminates
between vascular risk factors load and vascular component
quantified using WSTS and that neuroimaging of vascular lesions
is indeed important. Wahlund scale criteria thus being more
accurate in analysing the grade of vascular component observable
than classical FRS. It is interesting that WSTS, as a global brain
WMHs score, rather than basal ganglia sub-score, is associated
with an abnormal 123I-FP-CIT SPECT imaging. This suggests
that this technique can reflect vascular alterations other than
those affecting basal ganglia. The association observed between
abnormal 123I-FP-CIT SPECT and the vascular component
quantified by WSTS could be justified because dementia patients
have a significantly higher frequency of abnormal 123I-FP-
CIT SPECT, in particular, the PDD group seems to be the
responsible for this finding. PDD and LBD had the highest
frequency of abnormal 123I-FP-CIT SPECT and PDD showed
the second highest WSTS after mixed AD. Moreover, AD
showed a high vascular contribution (high mean WSTS) and
the frequency of abnormal 123I-FP-CIT SPECT was higher
(23%) than expected according to previous reports that confirm
the utility of 123I-FP-CIT SPECT in the differentiation of
PDD/LBD from AD (O’Brien et al., 2009; Cummings et al.,
2011). Some studies reported that approximately 5–10% of
123I-FP-CIT SPECT in patients with clinical dementia showed
intermediate scans. Thus, abnormal images within AD group
may represent mixed LBD/AD disease (Kemp and Holmes,
2007).
In conclusion, our study supports the utility of 123I-FP-
CIT SPECT to detect abnormal dopaminergic function in those
patients that showed a high WSTS corresponding to a high grade
of generalized ischemic brain lesions. This decrease uptake could
be due to the loss of dopaminergic innervation in the striatum
as a consequence of ischemia or the alteration of dopaminergic
system because of abnormal cell functionality, characteristic of
oxidative stress that could precede cell death in dementia or MCI
(Kim et al., 2012).
There is growing evidence demonstrating that the vascular
component has an active role in dementia mechanisms and its
progress and is probably involved in most dementia subtypes
which share similar physiopathological features (Iadecola and
Gorelick, 2003). Therefore, it is not surprising that an abnormal
123I-FP-CIT SPECT is associated with cerebrovascular lesions
related to dementia, but cannot differentiate among dementia
subtypes that have an important vascular component, such as
mixed AD, VaD or VP.
It is known that 123I-FP-CIT SPECT is useful to discriminate
AD from PDD/LBD, and hence to distinguish patients in
whom dopaminergic therapy may be beneficial (Varrone and
Halldin, 2010; Cummings et al., 2011). Therefore, an abnormal
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scan suggests underlying neurodegeneration, supportive of a
diagnosis of Parkinson’s disease, or atypical parkinsonism, LBD
and even VP if the nigrostriatal system is affected. Conversely, a
normal dopaminergic imaging supports an alternative diagnosis
such as AD, essential tremor or iatrogenic parkinsonism. In our
study, we demonstrated that 123I-FP-CIT SPECT could be also
useful to confirm diagnosis of dementia among those patients
with MCI.
Recent studies have demonstrated a 6–8% decline of DAT per
decade (Erixon-Lindroth et al., 2005), suggesting DAT binding
is a powerful mediator of age-related cognitive changes. These
findings should be taken under consideration when designing
and interpreting in vivo imaging studies.
Finally, this study did not find a significant association
between neuropsychological function and abnormal 123I-FP-
CIT SPECT nor high WSTS. This suggests that neither
measurement of vascular component score nor the functionality
of dopaminergic system can detect degree of cognitive decline in
our sample.
Limitations
It is important to note that patients with VaD in our sample
had lower FRS scores than expected; the distribution of CVRF
was low and they did not appear to have the highest WSTS-
being lower than those observed in AD, where cholesterol levels
seemed to be a risk factor to develop AD. This fact could be
due to the small number of patients in our sample, especially in
the VaD group. Another limitation of our study was the use of
clinical diagnosis as the gold standard, which may not always be
accurate.
Further studies are needed to better elucidate the potential
role of dopaminergic transporter imaging on detecting vascular
brain damage and its association with clinical dementia.
Conclusion
In agreement with previous reports 123I-FP-CIT SPECT imaging
is abnormal in patients with extrapyramidal signs (PDD and
DLB). Interestingly, around 20% of patients with pure AD or
MCI had abnormal SPECT. The new finding is that on initial
visit 123I-FP-CIT SPECT can differentiate severity in terms of
classification between MCI and dementia, thus helping establish
more accurately initial diagnosis and maybe providing a useful
tool to discriminate MCI from overall dementia at clinical
practice. Furthermore, in our sample, the vascular contribution is
shown to be relevant and present among AD and PDD patients,
in line with previously reported data and in addition, there is
a good correlation between uptake on 123I-FP-CIT SPECT and
ischemic score on MRI or CT.
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